Indianapolis-based Eli Lilly and Co. announced Thursday that it has received a Fast Track designation from the U.S. Food and Drug Administration to investigate its diabetes drug tirzepatide for the treatment of adults with obesity.
Michele Sawyer started Sept. 1 as chief financial officer at the Indiana Biosciences Research Institute after more than two decades at drugmaker Eli Lilly and Co. and its animal health spinoff, Elanco Animal Health.
Ian Nicolini, who has served as Indy Chamber’s chief operating officer since October 2020, is leaving his position to join a commercial real estate developer working to recruit businesses to a high-tech research district planned in Boone County.
In January, the cost of insulin for patients on Medicare will be capped at $35 a month. But that cap doesn’t apply to those with private insurance, which is used by the majority of those in need of insulin.
Indiana ended up with a rushed law that seemed to please few.
Despite negative impacts, Indiana’s largest employers didn’t weigh in publicly on the state’s new abortion law while it was being debated.
GOP lawmakers had earlier tried to offer their own, more scaled-back version of an insulin price limit, but Democrats rejected it as too narrow.
Indianapolis-based Eli Lilly and Co. said Indiana’s new abortion law could hinder its ability to attract diverse scientific, engineering and business talent to the state.
The cost to Indianapolis-based Eli Lilly and Co. would reach more than $183 million because cases brought under the False Claims Act triple the final judgment. Lilly said it plans to appeal and is confident that it will prevail.
Indianapolis-based Eli Lilly and Co. posted a profit of $1.13 billion, down from $1.68 billion a year ago, and cut its full-year profit guidance.
The stock sale is a primary way for the endowment, one of the largest private philanthropic foundations in the United States, to raise cash to make grants to arts, education, religious and community development organizations.
Like a kite that has caught a stiff breeze, Eli Lilly and Co. stock is having the ride of its life. Shares in the Indianapolis-based drugmaker have soared 41% in the past 52 weeks, to about $331 each.
Indianapolis-based Eli Lilly and Co. on Wednesday announced an agreement with the U.S. government to supply an additional 150,000 doses of its COVID-fighting antibody bebtelovimab.
The drugmaker is one of hundreds of U.S. companies being sued in the recent trend in litigation: excessive fees on 401(k) retirement plans.
A top human resources officer at Eli Lilly and Co.’s factory in New Jersey claims the drugmaker fired her in retaliation for investigating employee complaints about drug manufacturing problems and for refusing to drop the matter.
Lebanon Mayor Matt Gentry called Eli Lilly’s plans to build two pharmaceutical manufacturing sites “transformational” for his city.
The Indianapolis-based drugmaker said Wednesday the project in Boone County will create up to 500 jobs in central Indiana, along with up to 1,500 temporary construction jobs.
The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.
The pharmaceutical giant is turning heads with an experimental medicine it claims can help obese patients shed nearly a quarter of their body weight and manage diabetes.
David Ricks’ lunchtime speech to The Economic Club of Indiana—repeated on social media by those in attendance and reported by IBJ and local TV stations—has reverberated across the state.
